XTL Names Mr. Noam Band as its New Chief Executive Officer
XTL Biopharmaceuticals (Nasdaq: XTLB) has appointed Noam Band as its new Chief Executive Officer, while Shlomo Shalev continues as Chairman of the Board of Directors. Band brings significant experience from his previous roles, including serving as CEO and Chairman of Gix Internet and CEO of Dotomi.
Band holds an MBA and B.A. in Economics from The Hebrew University of Jerusalem. His background includes strategic business development, market expansion, and operational leadership positions. XTL currently operates through its wholly-owned subsidiary, The Social Proxy , a web data AI company developing an ethical proxy data extraction platform. The company also maintains a sublicensed IP portfolio for hCDR1 in Lupus treatment.
XTL Biopharmaceuticals (Nasdaq: XTLB) ha nominato Noam Band come nuovo Amministratore Delegato, mentre Shlomo Shalev continua a ricoprire il ruolo di Presidente del Consiglio di Amministrazione. Band porta con sé un'esperienza significativa dai suoi precedenti ruoli, tra cui quello di CEO e Presidente di Gix Internet e CEO di Dotomi.
Band possiede un MBA e una laurea in Economia presso l'Università Ebraica di Gerusalemme. Il suo background include lo sviluppo strategico del business, l'espansione del mercato e posizioni di leadership operativa. XTL opera attualmente attraverso la sua controllata interamente posseduta, The Social Proxy, un'azienda di dati web AI che sviluppa una piattaforma etica per l'estrazione dei dati proxy. L'azienda mantiene anche un portafoglio di IP in sublicenza per hCDR1 nel trattamento del Lupus.
XTL Biopharmaceuticals (Nasdaq: XTLB) ha nombrado a Noam Band como su nuevo Director Ejecutivo, mientras que Shlomo Shalev continúa como Presidente de la Junta Directiva. Band aporta una experiencia significativa de sus roles anteriores, incluyendo su cargo como CEO y Presidente de Gix Internet y CEO de Dotomi.
Band tiene un MBA y una licenciatura en Economía de la Universidad Hebrea de Jerusalén. Su experiencia incluye desarrollo estratégico de negocios, expansión de mercado y posiciones de liderazgo operativo. XTL opera actualmente a través de su subsidiaria de propiedad total, The Social Proxy, una empresa de datos web AI que desarrolla una plataforma ética de extracción de datos proxy. La empresa también mantiene un portafolio de propiedad intelectual sublicenciada para hCDR1 en el tratamiento del Lupus.
XTL Biopharmaceuticals (Nasdaq: XTLB)는 Noam Band를 새로운 CEO로 임명했으며, Shlomo Shalev는 이사회 의장직을 계속 유지합니다. Band는 Gix Internet의 CEO 및 의장, Dotomi의 CEO로서의 경험을 포함하여 상당한 경험을 가지고 있습니다.
Band는 예루살렘 히브리 대학교에서 MBA와 경제학 학사 학위를 취득했습니다. 그의 배경에는 전략적 비즈니스 개발, 시장 확장 및 운영 리더십 직책이 포함됩니다. XTL은 현재 전액 출자한 자회사인 The Social Proxy를 통해 운영되고 있으며, 이 회사는 윤리적인 프록시 데이터 추출 플랫폼을 개발하는 웹 데이터 AI 회사입니다. 이 회사는 또한 루푸스 치료를 위한 hCDR1에 대한 서브 라이센스 IP 포트폴리오를 유지하고 있습니다.
XTL Biopharmaceuticals (Nasdaq: XTLB) a nommé Noam Band comme nouveau Directeur Général, tandis que Shlomo Shalev continue d'exercer les fonctions de Président du Conseil d'Administration. Band apporte une expérience significative de ses précédents postes, notamment en tant que PDG et Président de Gix Internet et PDG de Dotomi.
Band détient un MBA et une licence en Économie de l'Université Hébraïque de Jérusalem. Son parcours inclut le développement stratégique des affaires, l'expansion du marché et des postes de leadership opérationnel. XTL opère actuellement à travers sa filiale entièrement détenue, The Social Proxy, une entreprise d'IA de données web qui développe une plateforme éthique d'extraction de données proxy. L'entreprise maintient également un portefeuille de propriété intellectuelle sous licence pour hCDR1 dans le traitement du Lupus.
XTL Biopharmaceuticals (Nasdaq: XTLB) hat Noam Band zum neuen CEO ernannt, während Shlomo Shalev weiterhin als Vorsitzender des Vorstands fungiert. Band bringt umfangreiche Erfahrungen aus seinen vorherigen Positionen mit, darunter die Rolle des CEO und Vorsitzenden von Gix Internet sowie CEO von Dotomi.
Band hat einen MBA und einen Bachelor-Abschluss in Wirtschaftswissenschaften von der Hebräischen Universität Jerusalem. Sein Hintergrund umfasst strategische Geschäftsentwicklung, Markterweiterung und operative Führungspositionen. XTL operiert derzeit über seine hundertprozentige Tochtergesellschaft, The Social Proxy, ein Unternehmen für Webdaten-AI, das eine ethische Plattform zur Datenextraktion entwickelt. Das Unternehmen verfügt auch über ein sublicenziertes IP-Portfolio für hCDR1 zur Behandlung von Lupus.
- Appointment of experienced CEO with proven track record in technology and business development
- Company maintains valuable IP portfolio for Lupus treatment (hCDR1)
- 100% ownership of The Social Proxy , providing AI and data extraction capabilities
- Multiple disclosed risks including uncertain sub-licensing revenue
- Operational challenges in integrating The Social Proxy subsidiary
- Competitive market pressures and potential operational cost increases
Brings a Wealth of Managerial Experience and Track Record
RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”) announced today the appointment of Noam Band as the Company’s new Chief Executive Officer. Shlomo Shalev will continue as the Chairman of the Board of Directors.
Previously, Mr. Band has served as the Chairman and Chief Executive Officer of Gix Internet Ltd. (formerly Algomizer Ltd.) (TASE:GIX), a publicly traded technology company specializing in online marketing, and as the Chief Executive Officer of Dotomi (acquired by ValueClick), where he oversaw operations and strategic initiatives in the digital marketing space. From 2020 through its acquisition in 2023 he served as a board advisor to 7digital Group plc (formerly AIM: 7DIG), contributing to its strategic direction and corporate governance. He has also served as the
Chief Executive Officer of Monitor2Heart He holds an MBA and a B.A. in Economics from The Hebrew University of Jerusalem.
“Noam’s expertise in strategic business development, market expansion, and operational leadership will be invaluable as XTL continues to grow and innovate”, Mr. Shalev stated. “The Board is confident that Mr. Band’s proven track record of success, visionary leadership, and deep industry expertise will drive XTL toward new opportunities and continued success. His appointment marks an exciting new chapter for the company, reinforcing its commitment to innovation, operational excellence, and delivering value to its shareholders and customers.”
About XTL Biopharmaceuticals Ltd.
XTL holds
Cautionary Note Regarding Forward-Looking Statements
This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this communication that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of the Company and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to (i) whether to the Company will be able to receive sub-licensing fees relating to its Hcdr1 intellectual property, (ii) the Company’s ability to successfully manage and integrate The Social Proxy and any other joint ventures, acquisitions of businesses, solutions or technologies; (iii) unanticipated operating costs, transaction costs and actual or contingent liabilities; (iv) the ability to attract and retain qualified employees and key personnel; (v) adverse effects of increased competition on the Company’s future business; (vi) the Company’s ability to protect its intellectual property; and (vii) local, industry and general business and economic conditions. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 20-F and current reports on Form 6-K filed by the Company with the Securities and Exchange Commission. The Company anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. The Company assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing the Company’s plans and expectations as of any subsequent date.
For further information, please contact:
Investor Relations, XTL Biopharmaceuticals Ltd.
Tel: +972 3 611 6666
Email: info@xtlbio.com
www.xtlbio.com
FAQ
What is Noam Band's background before joining XTLB as CEO?
What are XTL Biopharmaceuticals' (XTLB) main business operations?
Who replaced whom in the XTLB leadership change?
What are the main risks disclosed by XTLB in this announcement?
